Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for SUPN

Stock NameSupernus Pharmaceuticals Inc
TickerSUPN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS8684591089
LEI549300GRM36VBKISYJ58

Show aggregate SUPN holdings

News associated with SUPN

Contrasting Supernus Pharmaceuticals (NASDAQ:SUPN) and Evoke Pharma (NASDAQ:EVOK)
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) and Evoke Pharma (NASDAQ:EVOK – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability. Volatility & Risk Supernus Pharmaceuticals has a beta […] - 2025-09-04 02:30:48
Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Hold” at Zacks Research
Zacks Research upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a strong sell rating to a hold rating in a research report sent to investors on Tuesday morning,Zacks.com reports. Several other analysts also recently weighed in on SUPN. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $42.00 to $46.00 and gave […] - 2025-08-22 03:08:51
Maryland State Retirement & Pension System Trims Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Maryland State Retirement & Pension System lessened its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 13.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 16,094 shares of the specialty pharmaceutical company’s stock after selling 2,514 shares during […] - 2025-08-15 04:51:00
Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 1-Year High on Analyst Upgrade
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Free Report)’s share price hit a new 52-week high on Wednesday after Cantor Fitzgerald raised their price target on the stock from $42.00 to $46.00. Cantor Fitzgerald currently has an overweight rating on the stock. Supernus Pharmaceuticals traded as high as $41.51 and last traded at $42.29, with a […] - 2025-08-08 02:19:00
SUPN Crosses Above Average Analyst Target
In recent trading, shares of Supernus Pharmaceuticals Inc (Symbol: SUPN) have crossed above the average analyst 12-month target price of $40.20, changing hands for $42.44/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: down - 2025-08-07 12:32:22
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at Wall Street Zen
Wall Street Zen upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a hold rating to a buy rating in a research note released on Saturday morning. Separately, Cantor Fitzgerald raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $42.00 price objective for the company in a […] - 2025-08-05 02:56:51
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Wall Street Zen
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Sunday. Supernus Pharmaceuticals Stock Performance Shares of Supernus Pharmaceuticals stock opened at $33.23 on Friday. The firm has a fifty day moving average […] - 2025-07-22 02:55:51
Allspring Global Investments Holdings LLC Reduces Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Allspring Global Investments Holdings LLC lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 6.5% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 19,353 shares of the specialty pharmaceutical company’s stock after selling 1,356 shares during the quarter. […] - 2025-07-10 04:34:50
Robeco Institutional Asset Management B.V. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Robeco Institutional Asset Management B.V. bought a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 8,151 shares of the specialty pharmaceutical company’s stock, valued at approximately $267,000. Other […] - 2025-07-03 05:08:49
Illinois Municipal Retirement Fund Has $927,000 Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Illinois Municipal Retirement Fund decreased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 2.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 28,303 shares of the specialty pharmaceutical company’s stock after selling 730 shares […] - 2025-07-02 05:28:54
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stake Boosted by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC increased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 12.5% during the first quarter, HoldingsChannel reports. The firm owned 24,881 shares of the specialty pharmaceutical company’s stock after acquiring an additional 2,762 shares during the period. Exchange Traded Concepts LLC’s holdings in Supernus Pharmaceuticals were worth $815,000 at […] - 2025-06-20 05:21:54
Azzad Asset Management Inc. ADV Acquires New Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Azzad Asset Management Inc. ADV acquired a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,847 shares of the specialty pharmaceutical company’s stock, valued at approximately $552,000. A number of other […] - 2025-06-16 05:40:53
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Versant Capital Management Inc
Versant Capital Management Inc grew its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 6,931.3% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,125 shares of the specialty pharmaceutical company’s stock after purchasing an additional […] - 2025-06-06 05:45:08
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 19,824 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 24.7% during the 4th quarter, Holdings Channel reports. The firm owned 100,020 shares of the specialty pharmaceutical company’s stock after buying an additional 19,824 shares during the period. UBS […] - 2025-06-05 05:10:54
Millennium Management LLC Sells 222,273 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Millennium Management LLC decreased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 87.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,470 shares of the specialty pharmaceutical company’s stock after selling 222,273 shares during […] - 2025-06-05 04:25:01
Squarepoint Ops LLC Sells 475 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Squarepoint Ops LLC cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 2.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 20,492 shares of the specialty pharmaceutical company’s stock after selling 475 shares during the period. Squarepoint Ops LLC’s holdings in Supernus Pharmaceuticals were worth $741,000 at the end of […] - 2025-06-03 05:04:50
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 1,083 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 3.9% in the fourth quarter, HoldingsChannel.com reports. The fund owned 28,563 shares of the specialty pharmaceutical company’s stock after buying an additional 1,083 shares during the quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Supernus Pharmaceuticals […] - 2025-05-26 04:47:00
Graham Capital Management L.P. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Graham Capital Management L.P. bought a new position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 6,908 shares of the specialty pharmaceutical company’s stock, valued at approximately $250,000. […] - 2025-05-19 05:26:49
Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded at StockNews.com
StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a research note published on Friday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Get Our Latest Stock […] - 2025-05-19 02:38:47
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Acquired by Northern Trust Corp
Northern Trust Corp boosted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 18.3% in the fourth quarter, HoldingsChannel reports. The firm owned 717,161 shares of the specialty pharmaceutical company’s stock after purchasing an additional 110,867 shares during the quarter. Northern Trust Corp’s holdings in Supernus Pharmaceuticals were worth $25,933,000 as […] - 2025-05-12 04:49:02
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by First Trust Advisors LP
First Trust Advisors LP lessened its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 48.1% in the 4th quarter, Holdings Channel reports. The firm owned 27,019 shares of the specialty pharmaceutical company’s stock after selling 25,048 shares during the period. First Trust Advisors LP’s holdings in Supernus Pharmaceuticals were worth $977,000 […] - 2025-05-08 04:44:59
Barclays PLC Purchases 14,061 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Barclays PLC increased its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 12.9% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 122,849 shares of the specialty pharmaceutical company’s stock after buying an additional 14,061 shares during the period. Barclays PLC’s holdings in Supernus Pharmaceuticals were worth $4,442,000 at […] - 2025-04-28 04:59:03
Raymond James Financial Inc. Takes Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Raymond James Financial Inc. bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund bought 189,364 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,847,000. Raymond James Financial Inc. owned approximately […] - 2025-04-24 04:41:05
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Position Raised by Invesco Ltd.
Invesco Ltd. lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 4.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 508,069 shares of the specialty pharmaceutical company’s stock after acquiring an additional 22,027 shares during the period. Invesco Ltd. owned 0.92% of […] - 2025-04-20 05:22:48
JPMorgan Chase & Co. Acquires 44,414 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
JPMorgan Chase & Co. grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 17.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 297,810 shares of the specialty pharmaceutical company’s stock after purchasing an additional 44,414 shares during the quarter. […] - 2025-04-15 04:32:48
Arrowstreet Capital Limited Partnership Purchases 77,393 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Arrowstreet Capital Limited Partnership increased its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 79.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 174,916 shares of the specialty pharmaceutical company’s stock after acquiring an additional 77,393 shares during […] - 2025-04-08 05:01:05
Prudential Financial Inc. Has $2.37 Million Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Prudential Financial Inc. grew its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 14.3% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,733 shares of the specialty pharmaceutical company’s stock after buying an additional 8,352 shares […] - 2025-04-04 04:37:01
Sei Investments Co. Sells 16,825 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Sei Investments Co. cut its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 5.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 296,915 shares of the specialty pharmaceutical company’s stock after selling 16,825 shares during the period. Sei Investments Co.’s holdings in Supernus Pharmaceuticals were worth $10,736,000 at the end of […] - 2025-03-30 05:37:02
Swiss National Bank Has $3.92 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
Swiss National Bank lifted its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,400 shares of the specialty pharmaceutical company’s stock after purchasing an additional 800 shares during the quarter. […] - 2025-03-26 05:44:46
Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by StockNews.com
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Free Report) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued on Monday. Separately, Cantor Fitzgerald reiterated a “neutral” rating and issued a $36.00 price objective on shares of Supernus Pharmaceuticals in a research note on Wednesday, February 26th. Get Our Latest […] - 2025-03-26 03:58:55

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc SUPN holdings

DateNumber of SUPN Shares HeldBase Market Value of SUPN SharesLocal Market Value of SUPN SharesChange in SUPN Shares HeldChange in SUPN Base ValueCurrent Price per SUPN Share HeldPrevious Price per SUPN Share Held
2025-09-26 (Friday)5,439USD 255,796USD 255,796
2025-09-25 (Thursday)5,439USD 256,612SUPN holding increased by 435USD 256,6120USD 435 USD 47.18 USD 47.1
2025-09-24 (Wednesday)5,439USD 256,177USD 256,177
2025-09-17 (Wednesday)5,405USD 242,144SUPN holding increased by 4378USD 242,1440USD 4,378 USD 44.8 USD 43.99
2025-09-16 (Tuesday)5,405USD 237,766USD 237,766
2025-09-12 (Friday)5,371USD 244,166USD 244,166
2025-09-11 (Thursday)5,371SUPN holding increased by 68USD 250,611SUPN holding increased by 7628USD 250,61168USD 7,628 USD 46.66 USD 45.8199
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of SUPN by Blackrock for IE00B3VWM098

Show aggregate share trades of SUPN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-11BUY68 46.660* 33.86
2025-08-21SELL-17 43.320* 33.80 Profit of 575 on sale
2025-07-31BUY51 35.100* 33.74
2025-06-30SELL-34 31.520* 33.88 Profit of 1,152 on sale
2025-06-25SELL-17 31.240* 33.94 Profit of 577 on sale
2025-06-20SELL-34 32.280* 33.98 Profit of 1,155 on sale
2025-05-23BUY17 32.100* 34.23
2025-05-19SELL-17 33.050* 34.28 Profit of 583 on sale
2025-05-15SELL-51 32.480* 34.30 Profit of 1,749 on sale
2025-05-12SELL-17 32.150* 34.36 Profit of 584 on sale
2025-05-09SELL-17 31.700* 34.39 Profit of 585 on sale
2025-04-30SELL-17 32.480* 34.54 Profit of 587 on sale
2025-04-24SELL-34 31.350* 34.64 Profit of 1,178 on sale
2025-04-17SELL-17 30.760* 34.85 Profit of 592 on sale
2025-04-15SELL-51 31.460* 34.93 Profit of 1,781 on sale
2025-04-14SELL-51 31.600* 34.96 Profit of 1,783 on sale
2025-04-09SELL-68 31.760* 35.08 Profit of 2,385 on sale
2025-04-07SELL-119 32.270* 35.16 Profit of 4,184 on sale
2025-04-04SELL-170 32.740* 35.19 Profit of 5,982 on sale
2025-03-31BUY17 32.750* 35.29
2025-03-19SELL-34 32.030* 35.60 Profit of 1,210 on sale
2025-03-14SELL-102 31.260* 35.75 Profit of 3,647 on sale
2025-03-13SELL-34 31.170* 35.82 Profit of 1,218 on sale
2025-03-12SELL-578 31.380* 35.88 Profit of 20,739 on sale
2025-03-07SELL-34 32.070* 36.04 Profit of 1,225 on sale
2025-03-06SELL-51 31.820* 36.10 Profit of 1,841 on sale
2025-03-03SELL-17 31.740* 36.31 Profit of 617 on sale
2025-02-28SELL-102 32.060* 36.38 Profit of 3,710 on sale
2025-02-26SELL-17 31.910* 36.53 Profit of 621 on sale
2025-02-25SELL-51 32.810* 36.59 Profit of 1,866 on sale
2025-02-18BUY85 39.750* 36.83
2025-02-13BUY17 39.530* 36.68
2025-02-12BUY17 38.990* 36.63
2025-02-11BUY51 38.650* 36.59
2025-02-06BUY153 38.850* 36.47
2025-01-27BUY17 39.410* 35.94
2024-12-30BUY85 36.910* 35.73
2024-12-06BUY68 37.170* 35.62
2024-12-05BUY17 36.990* 35.57
2024-12-04BUY85 37.150* 35.52
2024-11-29BUY85 36.570* 35.34
2024-11-27BUY68 36.990* 35.20
2024-11-26BUY17 36.140* 35.16
2024-11-21BUY85 35.820* 35.02
2024-11-20BUY51 36.120* 34.96
2024-11-18BUY204 35.250* 34.90
2024-11-12BUY136 37.830* 34.71
2024-11-08BUY85 36.600* 34.57
2024-11-07BUY255 36.400* 34.43
2024-11-06BUY34 37.750* 34.16
2024-10-31BUY17 34.070* 34.05
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of SUPN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19122,1513301,18840.6%
2025-09-18121,7610267,52545.5%
2025-09-1770,393750204,21134.5%
2025-09-1692,8030275,02433.7%
2025-09-15117,876210292,58040.3%
2025-09-1256,904200164,68934.6%
2025-09-1180,78550192,70641.9%
2025-09-1097,2060247,18239.3%
2025-09-09103,40321,544214,67548.2%
2025-09-0894,0301,712217,57143.2%
2025-09-0565,260300193,61133.7%
2025-09-0487,4799,555199,60343.8%
2025-09-0371,5531,695171,33341.8%
2025-09-02151,60032,060318,69847.6%
2025-08-2978,3442,289147,46753.1%
2025-08-2896,124974162,32859.2%
2025-08-2798,4244,105244,87540.2%
2025-08-2668,3820134,61050.8%
2025-08-25114,0932,502258,41544.2%
2025-08-22170,4587,565320,38553.2%
2025-08-21126,8771,383256,89649.4%
2025-08-2097,552696267,86636.4%
2025-08-1996,5005,963208,44446.3%
2025-08-18104,7711,006285,51036.7%
2025-08-15124,03620,531334,97737.0%
2025-08-1483,0364,471360,72523.0%
2025-08-13143,7964,486408,81035.2%
2025-08-12120,422909359,23133.5%
2025-08-11112,8106,919330,27234.2%
2025-08-08228,44958,762395,64057.7%
2025-08-07334,0140923,64436.2%
2025-08-06692,0716,1101,667,36241.5%
2025-08-05248,6500476,50952.2%
2025-08-04162,9890229,99770.9%
2025-08-01250,1790326,68476.6%
2025-07-31433,277375912,33647.5%
2025-07-30158,3605215,82673.4%
2025-07-29188,5610455,53841.4%
2025-07-28160,9300241,81666.6%
2025-07-2598,8530302,32832.7%
2025-07-24122,0570194,07162.9%
2025-07-2362,1900125,50949.6%
2025-07-22141,5161,325343,16241.2%
2025-07-21197,0890471,96241.8%
2025-07-18105,7060300,27935.2%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.